Latest News

Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.

AI tools in pharmacy education risk eroding critical thinking, lab competency, and patient safety if used as substitutes for foundational learning.

The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.

Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.

Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.

Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.

Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.

Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.

Creating institution-specific, literacy-friendly chemotherapy education sheets resulted in patient education materials with higher readability scores than similar materials from common chemotherapy education sites.

Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.

In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.

Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.

As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.

How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.

At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.

Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.

In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence

Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.

A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.

The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.

Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.